California State Teachers Retirement System Has $9.51 Billion Holdings in IQVIA Holdings Inc. $IQV

California State Teachers Retirement System raised its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 18,735.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,241,537 shares of the medical research company's stock after acquiring an additional 48,980,106 shares during the period. California State Teachers Retirement System owned about 29.92% of IQVIA worth $9,514,450,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in IQV. BlackRock Inc. acquired a new stake in shares of IQVIA in the 2nd quarter valued at approximately $2,811,292,000. Geode Capital Management LLC lifted its stake in IQVIA by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company's stock valued at $982,272,000 after purchasing an additional 24,453 shares during the last quarter. Boston Partners lifted its stake in IQVIA by 14.9% in the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company's stock valued at $923,276,000 after purchasing an additional 530,672 shares during the last quarter. JPMorgan Chase & Co. boosted its position in IQVIA by 16.2% in the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company's stock valued at $856,468,000 after buying an additional 528,753 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of IQVIA by 15.3% during the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company's stock worth $526,891,000 after buying an additional 367,204 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on IQV. Mizuho increased their price target on IQVIA from $215.00 to $230.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Weiss Ratings upgraded IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, July 15th. BMO Capital Markets upped their target price on IQVIA from $210.00 to $270.00 and gave the stock an "outperform" rating in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research report on Thursday, July 9th. Finally, TD Cowen boosted their price target on IQVIA from $233.00 to $288.00 and gave the stock a "buy" rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, IQVIA has an average rating of "Moderate Buy" and a consensus target price of $243.62.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares of the company's stock, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the company's stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider owned 2,989 shares in the company, valued at $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 15,581 shares of company stock valued at $3,796,021. Corporate insiders own 1.70% of the company's stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $259.49 on Wednesday. The firm has a market cap of $42.71 billion, a PE ratio of 32.19, a price-to-earnings-growth ratio of 2.29 and a beta of 1.18. The firm's fifty day moving average is $233.34 and its 200-day moving average is $194.19. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $271.80.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA's quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the business posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.